Background
Low HbF expression in HbE-β
+
-thalassemia may lead to misdiagnosis of HbE heterozygosity. We aimed to characterize the β
-
and α-globin genes and the modifying factors related to HbF expression in patients with an Hb phenotype similar to that of HbE heterozygotes. Furthermore, screening tools for differentiating HbE-β
+
-thalassemia from HbE heterozygotes have been investigated.
Participants and Methods
A total of 2133 participants with HbE and HbA with varying HbF levels were recruited. Polymerase chain reaction-based DNA analysis and sequencing were performed to characterize β- and α-globin genes. DNA polymorphism at position −158 nt 5′ to
G
γ-globin was performed by
Xmn
I restriction digestion. Receiver operating characteristic (ROC) curves were constructed using the area under the curve (AUC). Cutoff values of HbA
2
, HbE, and HbF levels for the differentiation of HbE-β
+
-thalassemia from HbE heterozygotes were determined.
Results
Five β
+
-thalassemia mutations
trans
to β
E
-gene (β
−87(C>A)
, β
−31(A>G)
, β
−28(A>G)
, β
19(A>G)
, and β
126(T>G)
) were identified in 79 patients. Among these, 54 presented with low HbF levels, and 25 presented with high HbF levels. ROC curve analysis revealed an excellent AUC of 1.000 (95% confidence interval:1.000–1.000) for HbE levels, and a cut-off point of ≥35.0% had 100.0% sensitivity, specificity, and Youden’s index for differentiating HbE-β
+
-thalassemia from HbE heterozygotes. The proportion of α-thalassemia mutations was 46.3 and 8.0% among HbE-β
+
-thalassemia patients with low and high HbF levels, respectively. Two rare α-thalassemia mutations (Cap +14(C>G) and initiation codon (ATG>-TG)) of α
2
-globin genes were identified. The genotype and allele of the polymorphism at −158 nt 5′ to
G
γ-globin was found to be negatively associated with HbF expression.
Conclusions
HbE-β
+
-thalassemia cannot be disregarded until appropriate DNA analysis is performed, and the detection of α-thalassemia mutations should always be performed under these conditions. An HbE level ≥35.0% may indicate screening of samples for DNA analysis for HbE-β
+
-thalassemia diagnosis.